These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
378 related articles for article (PubMed ID: 1920939)
21. [Bone mass and biochemical parameters in metabolic bone diseases]. Negoro Y; Tomita A; Masahashi T; Suzuki M; Noguchi M; Nakanishi M Rinsho Byori; 1991 Sep; 39(9):934-9. PubMed ID: 1942567 [TBL] [Abstract][Full Text] [Related]
22. Role of vitamin D and parathyroid hormone in the regulation of bone turnover and bone mass in men: the MINOS study. Szulc P; Munoz F; Marchand F; Chapuy MC; Delmas PD Calcif Tissue Int; 2003 Dec; 73(6):520-30. PubMed ID: 12958693 [TBL] [Abstract][Full Text] [Related]
23. Serum BAP as the clinically useful marker for predicting BMD reduction in diabetic hemodialysis patients with low PTH. Ueda M; Inaba M; Okuno S; Maeno Y; Ishimura E; Yamakawa T; Nishizawa Y Life Sci; 2005 Jul; 77(10):1130-9. PubMed ID: 15978265 [TBL] [Abstract][Full Text] [Related]
25. Effect of raloxifene on parathyroid hormone in osteopenic and osteoporotic postmenopausal women with chronic kidney disease stage 5. Haghverdi F; Farbodara T; Mortaji S; Soltani P; Saidi N Iran J Kidney Dis; 2014 Nov; 8(6):461-6. PubMed ID: 25362221 [TBL] [Abstract][Full Text] [Related]
26. Close association between parathyroid hormone and left ventricular function and structure in end-stage renal failure patients under maintenance hemodialysis. Nasri H; Baradaran A J Ayub Med Coll Abbottabad; 2004; 16(2):3-8. PubMed ID: 15455608 [TBL] [Abstract][Full Text] [Related]
27. Prevalence and patterns of bone loss in the first year after renal transplant in South East Asian patients. Lim DS; Kee TY; Fook-Chong S; Zhang RF; Chandran M Transplantation; 2011 Sep; 92(5):557-63. PubMed ID: 21832963 [TBL] [Abstract][Full Text] [Related]
28. [Markers of calcium--phosphate metabolism and bones alterations in long term kidney transplant patients]. Spiechowicz U; Kokot F; Wiecek A Przegl Lek; 2003; 60(11):690-4. PubMed ID: 15058034 [TBL] [Abstract][Full Text] [Related]
29. Correlations and time course of FGF23 and markers of bone metabolism in maintenance hemodialysis patients. Bielesz BO; Hecking M; Plischke M; Cejka D; Kieweg H; Haas M; Marculescu R; Hörl WH; Bieglmayer C; Sunder-Plassmann G Clin Biochem; 2014 Sep; 47(13-14):1316-9. PubMed ID: 24956265 [TBL] [Abstract][Full Text] [Related]
30. [Effect of salmon calcitonin on bone mineral density and calcium-phosphate metabolism in chronic hemodialysis patients with secondary hyperparathyroidism]. Matuszkiewicz-Rowińska J; Niemczyk S; Przedlacki J; Puka J; Switalski M; Ostrowski K Pol Arch Med Wewn; 2004 Jul; 112(1):797-803. PubMed ID: 15526839 [TBL] [Abstract][Full Text] [Related]
31. Bone mineral recovery after parathyroidectomy in patients with primary and renal hyperparathyroidism. Abdelhadi M; Nordenström J J Clin Endocrinol Metab; 1998 Nov; 83(11):3845-51. PubMed ID: 9814456 [TBL] [Abstract][Full Text] [Related]
32. Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1-84), and bone mineral content in dialysis patients. Jespersen B; Jensen JD; Nielsen HK; Lauridsen IN; Andersen MJ; Poulsen JH; Gammelgaard B; Pedersen EB Nephrol Dial Transplant; 1991; 6(2):98-104. PubMed ID: 1857534 [TBL] [Abstract][Full Text] [Related]
33. Bone mineral density and bone metabolism in hemodialysis patients. Correlation with PTH, 25OHD3 and leptin. Polymeris A; Doumouchtsis K; Grapsa E Nefrologia; 2012; 32(1):73-8. PubMed ID: 22130208 [TBL] [Abstract][Full Text] [Related]
34. [Efficacy and safety of long-term and low-dose desferrioxamine therapy against hyperaluminemia and the clinical symptoms associated with hyperaluminemia in patients undergoing maintenance hemodialysis]. Kuramochi G Nihon Jinzo Gakkai Shi; 1989 Mar; 31(3):267-73. PubMed ID: 2739124 [TBL] [Abstract][Full Text] [Related]
35. Measurement of PTH fragments for assessment of renal bone disease in hemodialysis patients. Fehr T; Garzoni D; Staub T; Binet I; Wüthrich RP Kidney Blood Press Res; 2006; 29(3):175-81. PubMed ID: 16931896 [TBL] [Abstract][Full Text] [Related]
36. Can low-dosage aluminium hydroxide control the plasma phosphate without bone toxicity? Jenkins DA; Gouldesbrough D; Smith GD; Cowie JF; Winney RJ Nephrol Dial Transplant; 1989; 4(1):51-6. PubMed ID: 2494599 [TBL] [Abstract][Full Text] [Related]
37. Total and regional bone mineral density by dual photon absorptiometry in patients on maintenance hemodialysis. Asaka M; Iida H; Entani C; Fujita M; Izumino K; Takata M; Seto H; Sasayama S Clin Nephrol; 1992 Sep; 38(3):149-53. PubMed ID: 1395168 [TBL] [Abstract][Full Text] [Related]
38. Bone metabolism and daily physical activity in women undergoing hemodialysis. Ota S; Takahashi K; Taniai K; Makino H Nihon Jinzo Gakkai Shi; 1997 May; 39(4):441-6. PubMed ID: 9198369 [TBL] [Abstract][Full Text] [Related]
39. Bone aluminum deposition in maintenance dialysis patients treated with aluminium-free dialysate: role of aluminium hydroxide consumption. Heaf JG; Pødenphant J; Andersen JR Nephron; 1986; 42(3):210-6. PubMed ID: 3945361 [TBL] [Abstract][Full Text] [Related]
40. Estimation of bone mineral density and architectural parameters of the distal radius in hemodialysis patients using peripheral quantitative computed tomography. Hasegawa K; Hasegawa Y; Nagano A J Biomech; 2004 May; 37(5):751-6. PubMed ID: 15047004 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]